U.S. Anti-nuclear Antibody Test Market – Industry Trends and Forecast to 2025

  • Pharmaceutical
  • Published Report
  • Feb 2018
  • North America
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
U.S. Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software & Services), By Technique (ELISA, Immunofluorescence Assay, Multiplex Assay), By Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Scleroderma), By End User (Hospitals, Clinical Laboratories, Physician Office Laboratories), By Country – Industry Trends and Forecast to 2025 U.S. Anti-Nuclear Antibody Test Market will reach USD 846.40 million by 2025 from USD 473.10 million in 2017 with a CAGR of 7.6% in the forecast period of 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

U.S. Antinuclear Antibody Test MarketThe major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection are boosting the growth of the antinuclear antibody test market.

Market Segmentation: U.S. Anti-nuclear Antibody Test Market

  • The antinuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the U.S. antinuclear anti body test market with 50.2% market share and is expected to reach USD 432.80 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.
  • The U.S. antinuclear anti-body test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the antinuclear antibody test market with 44.0% market share and is expected to reach USD 347.13 million by 2025, with the CAGR of 6.6% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 8.9% in the forecast period, and is expected to reach USD 217.89 million in 2025 from USD 110.70 million in 2017.
  • The U.S. anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the US anti-nuclear antibody test market with 26.2% market share and is expected to reach USD 239.47 million by 2025, at the highest CAGR of 8.8% in the forecast period 2018 to 2025.
  • The antinuclear anti body test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the U.S. antinuclear anti body test market with 45.9% market share and is expected to reach USD 396.88 million by 2025, at the highest CAGR of 8.0% in the forecast period 2018 to 2025.

Key Drivers: U.S. Anti-nuclear Antibody Test Market

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection are boosting the growth of the US anti-nuclear antibody test market.

Key Points: U.S. Anti-nuclear Antibody Test Market

In 2017, the U.S. antinuclear anti body test market is dominated by Alere, Inc., followed by Bio-Rad Laboratories and ThermoFisher Scientific, Inc.

Assay Kits & Reagents is dominating the anti-nuclear antibody test market.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART